{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-056758","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2026-08-13T20:22:35+00:00","discovered_at":"2026-08-13T20:24:04.331278+00:00","generated_at":"2026-08-13T20:24:31.772939+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CAMP4 Q2 net loss $33.5M; CMP-002 trial cleared in Australia/Argentina; $50.1M raised","bullets":["Net loss $33.5M vs $12.6M YoY; includes $20.9M non-cash loss on derivative tranche liability.","Cash $86.4M at June 30, 2026; plus $50.1M from second closing extends runway to end 2028.","Regulatory clearance from TGA/HREC (Australia) and ANMAT (Argentina) for Phase 1/2 CMP-002 trial; initiation expected Q4 2026.","R&D expenses $10.8M vs $10.3M; G&A $4.3M vs $4.2M.","HQ relocated to Watertown, Mass.; Analyst Day Sept 28, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-056758","json":"https://secwatch.observer/filing/0001628280-26-056758.json","markdown":"https://secwatch.observer/filing/0001628280-26-056758.md","text":"https://secwatch.observer/filing/0001628280-26-056758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026056758/0001628280-26-056758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026056758/camp-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:24:31.772939+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}